Skip to main content

zunveyl

Generic: benzgalantamine

zunveyl: developed by 1 company · 1 clinical trial tracked · 1 FDA decision.

zunveyl evidence translation

What we can confirm

1 FDA record · 1 tracked trial

What it means

Source-backed records connect zunveyl to ACOG; that link alone does not prove the drug works.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

How could zunveyl → ACOG affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Alzheimer Disease

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)
CompanyPhase
Alpha Cognition Inc. (ACOG)
Alzheimer Disease
Phase 4
Clinical Trials (1)

RESOLVE: A Phase 4, Open-label Study to Assess the Effect of Zunveyl on Safety and Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Adults With Mild to Moderate Alzheimer's Disease

NCT07633470·Phase 4·ACOG
Recruiting

Primary endpoint: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

Interventionalopen150 targetStarted 2026-05Completion 2027-0414 sites · United StatesAlpha Cognition, Inc
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE ZUNVEYL is indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults. ZUNVEYL is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults ( 1 )(ACOG)FDA ↗
NDA218549Type 2 - New Active Ingredient and Type 3 - New Dosage FormStandardOralTablet, Delayed Release

Frequently asked questions

Who is developing zunveyl?

zunveyl is being developed by Alpha Cognition Inc..

How many clinical trials involve zunveyl?

BioSniper tracks 1 clinical trial involving zunveyl.

What is zunveyl's latest FDA decision?

The most recent tracked FDA decision for zunveyl is Approval for 1 INDICATIONS AND USAGE ZUNVEYL is indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults. ZUNVEYL is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults ( 1 ), dated July 26, 2024.